India, Dec. 4 -- Lupin as entered into an Exclusive Licensing Agreement with Valorum Biologics (Valorum), a biosimilar specialist in the U.S., for its biosimilar Armlupeg' (pegfilgrastim-unne).Under the terms of the agreement, Valorum will advance the commercialization and distribution of Armlupeg' (pegfilgrastim-unne) in the United States. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.Pegfilgrastim-unne is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Published by HT Digital Content Services with permission from Pivotal Sources....